Table 1 Demographics and scores by sex of parent, subtype of disease and duration of methotrexate use
From: Improvement in medication education in a pediatric subspecialty practice
Characteristic | n= 100 (%) | Initial | n= 67 (%) | Follow-Up |
|---|---|---|---|---|
Sex of parent1 | ||||
Female | 73 (73%) | 77.3 ± 20.9 | 49 (73%) | 93.5 ± 11.1 |
Male | 27 (27%) | 71.9 ± 18.6 | 18 (27%) | 93.3 ± 9.7 |
Diagnosis1 | ||||
Oligoarticular: Persistent | 34 (34%) | 74.1 ± 21.2 | 21 (31%) | 94.3 ± 11.2 |
Oligoarticular: Extended | 5 (5%) | 64.0 ± 35.8 | 4 (6%) | 95.0 ± 10.0 |
Polyarticular: RF (-) | 39 (39%) | 81.0 ± 18.3 | 25 (38%) | 96.0 ± 8.2 |
Polyarticular: RF (+) | 4 (4%) | 75.0 ± 25.2 | 3 (4%) | 93.3 ± 11.5 |
Enthesitis-related | 6 (6%) | 76.7 ± 15.1 | 5 (7%) | 88.0 ± 11.0 |
Psoriatic | 10 (10%) | 70.0 ± 14.1 | 7 (11%) | 91.4 ± 10.7 |
Systemic | 2 (2%) | 60.0 ± 28.3 | 2 (3%) | 70.0 ± 14.1 |
MTX duration, months1 | ||||
2-6 | 26 (26%) | 75.4 ± 18.2 | 14 (21%) | 95.7 ± 11.6 |
7-12 | 15 (15%) | 74.7 ± 17.7 | 13 (20%) | 89.2 ± 10.4 |
13-24 | 21 (21% | 81.9 ± 18.9 | 13 (20%) | 92.3 ± 13.0 |
25-36 | 14 (14%) | 80.0 ± 24.8 | 9 (13%) | 97.8 ± 6.7 |
37-48 | 11 (11%) | 72.7 ± 20.5 | 9 (13%) | 95.6 ± 8.8 |
>48 | 13 (13%) | 66.2 ± 23.6 | 9 (13%) | 91.1 ± 10.2 |